



Beaumont
Pharma

Carbon Reduction Plan

Supplier name: Beaumont Pharma Ltd

Publication date: 07.04.2025

Commitment to achieving Net Zero

Beaumont Pharma Ltd is committed to achieving Net Zero emissions by 2040

Baseline Emissions Footprint

The baseline emissions below are the reference point against which our future emissions reduction will be measured.

Baseline Emissions Year 2023

Scope 1

Beaumont Pharma Ltd is a virtual distribution company which owns no assets directly involved in generation of GHG emissions. Beaumont Pharma does not manufacture products. All employees and contractors work remotely from their homes and our supply chain is managed entirely on an out-sourced basis. Emissions in this Scope are NIL

Scope 2

Total estimated emissions from purchase of electricity and gas for the home-based office is **13,340kgCO₂e**

Scope 3

- Business travel is estimated at 2,000 miles per year, equivalent to **616kgCO₂e**
- Employee commuting is zero
- Waste generated in operations is zero
- Upstream emissions from transportation and distribution are estimated from data provided by our partner organisations and are **20,550kgCO₂e**
- Downstream transportation and distribution emissions attributable to Beaumont Pharma Ltd by our pre-wholesale partner Alloga were **6,367 kgCO₂e** in 2023

Total emissions for baseline year 2023

40,873kgCO₂e

Current Emissions Reporting for 2024

Scope 1

Beaumont Pharma Ltd is a virtual distribution company which owns no assets directly involved in generation of GHG emissions. Beaumont Pharma does not manufacture products. All employees and contractors work remotely from their homes and our supply chain is managed entirely on an out-sourced basis. Emissions in this Scope are NIL

Scope 2

Current estimate is **12,006kgCO₂e**. We estimate that the projects implemented in 2024 have achieved a c.10% reduction in scope 2 emissions versus the 2023 baseline.

Scope 3

- Business travel for 2024 was estimated at 1,550 miles per year, equivalent to **477kgCO₂e**
- Employee commuting is zero
- Waste generated in operations is zero
- Upstream emissions from transportation and distribution are estimated from data provided by our partner organisations for 2023 these were **20,550kgCO₂e**. We do not currently have updated figures from all of our outsourcing partners for 2024 but our own Scope 3 emissions will be updated as soon as they are available.
- Downstream transportation and distribution emissions estimated as attributable to Beaumont Pharma Ltd by our pre-wholesale partner Alloga were **5,310 kgCO₂e** for 2024. This represents a reduction of 16% compared with baseline year 2023 resulting from utilisation of 100% renewable electricity sources.

Total emissions for 2024 (estimated)

38,343 kgCO₂e – this represents a 6% reduction overall compared with 2023.

Emissions reduction targets

With 2023 as baseline year, 2024 was our first full year of implementing projects to reduce our carbon footprint during which a project was completed to change to LED lighting through the house and office to reduce Scope 2 emissions. We use our home as our place of work and have allocated 50% of our total energy usage to Beaumont Pharma Ltd. In order to continue our progress towards achieving Net Zero by 2040, we have set a target of making a further 2% reduction in Scope 2 emissions in 2025.

Regarding Scope 3 emissions, we have contacted business partners in our supply chain to request information regarding their initiatives and any data which they have for downstream emissions. We use Alloga UK as our pre-wholesaler which means that we can attribute the large majority of our downstream indirect emissions there. Alloga have reduced their emissions through use of 100% renewable electricity sources.

We project that carbon emissions will decrease over the next four years to 24,250kgCO₂e by 2028. This is a reduction of 30%.

Carbon Reduction Projects

The following environmental management measures and projects are in progress in year 2025:

- Increased use of public transport where possible, reducing consumption of petrol
- Beaumont Pharma Ltd continues to request information from our partners regarding their supply chains and the efforts they are making to reduce their carbon footprints. We have informed them that we expect to see a real commitment to this and that we will consider switching partners if there is no evidence to this effect.

These measures will be in effect when performing the contract throughout the current year.

Declaration and Sign Off


This Carbon Reduction Plan has been completed in accordance with PPN 06/21 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting².

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard³.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors.

Signed on behalf of the Supplier:

A handwritten signature in black ink, appearing to read 'Dr Jane Sharples', is written over a horizontal dotted line.

Dr Jane Sharples⁴
Managing Director
Beaumont Pharma Ltd
Date: 07.04.25

¹<https://ghgprotocol.org/corporate-standard>

²<https://www.gov.uk/government/collections/government-conversion-factors-for-company-reporting>

³³<https://ghgprotocol.org/standards/scope-3-standard>